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Objective: Vagus Nerve Stimulation (VNS) has shown great promise as a potential therapy for a number
of conditions, such as epilepsy, depression and for Neurometabolic Therapies, especially for treating
obesity. The objective of this study was to characterize the left ventral subdiaphragmatic gastric trunk
of vagus nerve (SubDiaGVN) and to analyze the influence of intravenous injection of gut hormone
cholecystokinin octapeptide (CCK-8) on compound nerve action potential (CNAP) observed on the
same branch, with the aim of understanding the impact of hormones on VNS and incorporating the
methods and results into closed loop implant design. Methods: The cervical region of the left vagus nerve
(CerVN) of male Wistar rats was stimulated with electric current and the elicited CNAPs were recorded
on the SubDiaGVN under four different conditions: Control (no injection), Saline, CCK1 (100 pmol/kg)
and CCK2 (1000 pmol/kg) injections. Results: We identified the presence of Aδ, B, C1, C2, C3 and
C4 fibers with their respective velocity ranges. Intravenous administration of CCK in vivo results in
selective, statistically significant reduction of CNAP components originating from A and B fibers, but
with no discernible effect on the C fibers in n = 7 animals. The affected CNAP components exhibit
statistically significant (pSaline−CCK1 = 0.02 and pSaline−CCK2 = 0.007) higher normalized stimulation
thresholds. Conclusion: This approach of characterizing the vagus nerve can be used in closed loop
systems to determine when to initiate VNS and also to tune the stimulation dose, which is patient-
specific and changes over time.
Keywords: Compound nerve action potentials; subdiaphragmatic vagus nerve; vagus nerve stimulation;
closed loop system.
1. Introduction
The vagus nerve is the longest cranial nerve origi-
nating directly from the brain and branching down-
wards into the body. It emerges from the medulla
oblongata, traveling along the two lateral sides of
the body, innervating organs in thoracic and abdom-
inal regions.1 The vagus nerve acts as a conduit
for information exchange in the form of neural
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signals between the brain and the organs it inner-
vates. Neuromodulation2 is an emerging therapeu-
tic treatment modality for a number of intractable
diseases. The multifunctional and highly distributed
nature of the vagus nerve has led to vagus nerve stim-
ulation (VNS) being explored as a neuromodulatory
therapeutical target for a number of applications
ranging from pharmocoresistant eplilepsy, depression
to obesity.3–6 An emerging neuromodulatory obesity
management technique is VNS.7
Vagal afferents in the gastrointestinal (GI) tract
play an important role in determining meal sizes,
with mechanosensitive vagal afferents responding
to distension and chemosensitive vagal afferents
responding to nutrient type and quantity.8 VNS
has shown traction in reducing weight with mini-
mal invasiveness and surgical impact on the body.
Data from ReCharge (2011–2013)5 and EMPOWER
(2011)9 studies have demonstrated the clinical fea-
sibility of using VNS as an obesity management
technique and have also supported commercially
available solutions such as the VBLOC MaestroTM
system, a VNS implant for obesity management by
EnteroMedicsTM. The implant, recently approved by
FDA, can be surgically placed with the help of lapro-
scopic techniques, hence, it is surgically less invasive
compared to gastric bypass surgery (GBS).10
Majority of VNS applications involve open loop
stimulation. However, studies have shown that open
loop VNS, where stimulation parameters are pre-
programmed and not affected by patient’s physiolog-
ical condition, leads to modest weight loss only.5,6,9
Modest success rates have impeded the adoption of
VNS as a low risk, low cost replacement to GBS.6
Within a closed loop neuromodulation paradigm,
the initiation of stimulation and the dosage of stim-
ulation are controlled by physiological events.11 In
the context of weight loss, an implant with closed
loop capabilities is Intrapace abilitiTMwhich initiates
Gastric Electrical Stimulation (GES) in response
to transit of food in the stomach, such as during
meal intake.12 Another implant, the DiamondTM
(Metacure) system, stimulates the gastric antrum
when food is ingested in the stomach. It has also
shown greater weight loss capability than open loop
implants.13 Both implants do not stimulate the vagus
nerve directly, however, the stimulation might be
affecting vagal afferents in the stomach wall.
Recent studies on VBLOCTM, the only com-
mercially available Gastric-VNS implant, indicated
that a possible mechanism with which VNS using
VBLOCTMleads to weight loss is by blocking efferent
fibers carrying vagal signals to the gut.14 In this
paper, an effort has been made to determine if
gut hormone signaling through vagal afferents can
be used within the closed loop VNS modality. Gut
hormones such as cholecystokinin (CCK), glucagon,
glucagon-like peptide-1 (GLP-1) are considered to
be essential in appetite regulation. CCK plays an
important role in the complex negative feedback
to the brain to initiate meal termination.15 Pre-
vious work16,17 has suggested that CCK leads to
appetite suppressive effect. It activates CCKA recep-
tors which are expressed on afferent terminals of the
vagus nerve present in the gut.10 CCK introduced
exogenously also leads to satiation, reduced motility,
release of gastric and pancreatic enzymes involved in
digestion.10
By detecting the release of gut hormones through
compound nerve action potentials (CNAPs) and ini-
tiating VNS, there is a possibility to automate the
initiation of stimulation. Also, analysis of CNAPs
and interrogating the state of the nerve will enable
better control of stimulation dosage.18 The start of
high frequency VNS, such as VBLOCTM in relation
to release of gut hormones may have the potential
of amplifying the satiety-related impact of gut hor-
mones.
It has also been demonstrated that the satiating
effect of CCK-8 is reduced after abdominal vagotomy
leading to the conclusion that vagal afferents play an
important role in producing the satiation response in
conjunction with CCK.19 As the subdiaphragmatic
gastric trunk of vagus nerve (SubDiaGVN) is respon-
sible for carrying afferent signals from the gut to the
brain and efferent signals from the brain to the gut,
in this paper, we explore the possibilities of interro-
gating the SubDiaGVN branch, by electrical stimu-
lation at a distant location and recording locally, to
determine the presence of different fiber types and to
correlate the CNAP response with the physiological
condition of the targeted organ (e.g. stomach), and
develop a bio-marker for providing feedback to the
VNS device.
The eventual goal is to identify the effect of CCK
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VNS to affect appetite early on. Hence, we charac-
terize the SubDiaGVN branch of the vagus nerve, by
determining the different fiber types present, respec-
tive velocity ranges for each fiber type and its relative
stimulation threshold based on CNAPs observed in
response to electrical neural stimulation under four
physiological conditions: Control, Saline, CCK1 and
CCK2. Prechtl et al.20 have shown that, anatomi-
cally in the abdominal vagus of rats, 28% of the fibers
are motor fibers (A and B fibers) and 72% fibers are
sensory fibers (C fibers).21
Due to the differences in velocities for different
fiber types, CNAPs can be used as a method to deter-
mine activity originating from different fiber types
and their respective stimulation thresholds which
can be used to determine the optimal stimulation
dose. Nerve conduction velocities are also used to
assess nerve damage due to demylenation or axonal
degeneration.21 This is followed by an analysis of
the impact of different physiological conditions (Con-
trol i.e. no injection, Saline and CCK injection) on
CNAP metrics (such as amplitude, activation thresh-
old, etc.).
CNAPs were chosen because of their larger signal
amplitude (≥5 µV), compared to measuring sub-µV
neural mass activity changes; a significant challenge
to detect with even the current state-of-the-art in
neural recording technology. Due to the differences
in conduction velocities for different fiber types,
CNAPs can be used to determine activity originating
from different fiber types and their respective stim-
ulation thresholds. This can be used to adjust the
optimal stimulation dose. In general, nerve conduc-
tion velocities are also used to assess nerve damage
due to demyelination or axonal degeneration. In sum-
mary, Sec. 2 describes the in vivo experimental setup
used. Section 3 gives a detailed description of the
analytical methods used to analyze the experimental
data. The results are presented in Sec. 4 followed by
a discussion in Sec. 5.
2. Methods
All surgical and experimental protocols were per-
formed in accordance with the Animal (Scientific
Procedures) Act 1986 and following local ethical
approval.
2.1. In vivo experimental methods
2.1.1. Animals
Male Wistar Rats, obtained from Charles River, were
used in all experiments. The animals (n = 7) were
permitted ad libitum access to food and water and a
12 h light:dark cycle was maintained over them.
2.1.2. Cervical region of the left vagus nerve
(CerVN) and SubDiaGVN preparation
Rats were anesthetized with isoflourane followed
by urethane (20 mg · kg−1) which was infused at
a slow rate over 25min. Urethane was chosen as
evidence which appears to suggest that it does
not affect peripheral nerve activity.22 Urethane also
gives a very stable anesthetic state throughout the
procedure compared to other anesthetics such as
pentobarbital or ketamine/xylacine and has been
used in previous CCK-8 studies.19 In order to assess
full anesthesia state, the absence of forepaw pinch
reflex was verified. During the procedure, heart rate
and oxygen saturation were monitored through a
pulse oximeter (Physiosuite, Kent Scientfic). The
body temperature was maintained at 37 ± 1◦C by
using a heat pad and measured with a rectal ther-
mistor (Physiosuite, Kent Scientific).
After full anesthetization, a midline incision was
made to expose the CerVN branch for stimulation.
In order to record from the SubDiaGVN, a midline
incision was made in abdomen. The connective tissue
around the liver was gently removed. A large cot-
ton bud was used to gently displace the liver. The
liver was not bruised in the procedure and was eas-
ily put back in place. The esophagus and the anterior
SubDiaGVN, present nearby between the diaphragm
and top of the stomach, were exposed. A thread was
used to lift the nerve, and a recording electrode was
placed under the SubDiaGVN, just below the hepatic
branch, as the subdiagphragmatic ventral trunk just
enters the stomach (for more details, see Fig. A.1).
A pseudo-tripolar cuff electrode was placed under
the left cervical vagus nerve for stimulation. A pair
of similar bipolar electrodes were placed, in the cer-
vical cavity and subdiaphragmatic cavity on the
nearby tissue to capture any in-band interferences
due to movement or electromyographic (EMG) activ-
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Because interferences are common to vagus and ref-
erence channels and CNAPs are present only on the
vagus recording channel, it is possible to separate
CNAPs from interferences.
The approximate distance between stimulation
and recording electrodes was 8±0.5 cm. The cavities
were filled with paraffin oil as an insulation medium
as described in previous papers.23–26
2.1.3. Electrodes
The bipolar recording electrodes were fabricated in-
house by utilizing temper annealed 125 µm plat-
inum (Pt) wires (Advent Research Materials). The
Pt wires were cleaned by heating them to very high
temperature with a flame torch. After cleaning, the
Pt wire was soldered to a stainless steel wire. Multi-
ple layers of heat shrink were applied to the junction
of Pt and steel wire. In order to seal the junction,
the open ends of the heat shrink were sealed using
Araldite glue. A similar procedure was followed for
pseudo-tripolar stimulation electrodes.
2.1.4. Physiological conditions
The studies involving CCK comprise of recording
CNAPs under four different conditions with regards
to intravenous injections: Control is the condition
where no intravenous injection takes place, Saline is
the condition after injection of saline solution. Two
different doses of CCK-8 (Tocris Biosciences, UK)
were injected: a low dose of 100pM per kg (condition
CCK1) and a high dose of 1000pM per kg (condi-
tion CCK2). Prior to injection, CCK-8 was dissolved
in saline and the required amount was drawn into
250 µL syringe (Hamilton). The CCK dose was deliv-
ered through a tail vein cannula followed by a flush
of 250 µL saline.
2.2. Recording and stimulation setup
Figure 1 shows an overview of the experimental
setup.
Vagal nerve CNAPs were recorded using the
Intan RHD 2132 Electro-physiological recording
chip. For data acquisition, RHD 2000 Amplifier Eval-
uation system and software were utilized. The RHD
2132 has 16 bipolar channels out of which 3 channels
were utilized. One of the channels was used to record















































Fig. 1. The stimulation and recording setup positioned
at the left cervical and subdiaphragmatic branches of the
vagus nerve, respectively (left). A typical biphasic stim-
ulus (pulsewidth τpw and amplitude Istim) and recorded
CNAP (right) are shown.
were used as reference channels in the cervical and
subdiaphragmatic cavities.27 The cervical reference
channel ensured that stimulation of CerVN did not
lead to stimulation of nearby neck muscles, hence
loss of stimulation strength. The stimulation artifact
observed in the subdiaphragmatic reference channel
and the vagus recording channel helped in aligning
waveforms in time (Fig. A.2).
The stimulation and recording equipment were
connected to a single grounding point, as in
star grounding configuration. The animal was also
grounded to this single ground point by placing a
silver–silver chloride (Ag/AgCl) electrode under the
skin of the animal. On the ventral side, a differen-
tial bipolar recording configuration was implemented
to ensure better rejection of common mode signals.
A digital bandpass filter (200Hz–7.2 kHz) was also
activated using the RHD2000 Amplifier Evaluation
software to match the bandwidth of CNAPs and
reduce noise in the neural recording. In order to
remove line interference, a 50Hz digital notch filter
was activated using RHD 2000 Amplifier Evaluation
software. A current stimulation setup was designed
by using Keithley 6221 current source (Tektronix).
The programmable stimulation protocols were down-
loaded into the Keithley 6221 through a MATLAB
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2.2.1. Stimulation protocol
During each injection condition, the same CerVN
stimulation protocol was followed in which bipha-
sic current pulses were used. The pulsewidths
were τpw = 0.1, 0.2, 0.5, 1 and 5ms. For every
pulsewidth, the stimulation current Istim was cycled
through 16 different values. For pulsewidths 0.1ms
and 0.2ms, the stimulation current ranges from
0.2mA up to 3 mA: Istim = 0.2, 0.5, 0.8, 1–1.8mA
(∆Istim = 0.1mA), 1.8–3mA (∆Istim = 0.2mA). For
pulsewidths 0.5, 1 and 5 ms, the stimulation current
ranges from 0.1mA up to 2 mA Istim = 0.1–1.2mA
(∆Istim = 0.1), 1.2–2mA (∆Istim = 0.2). The stim-
ulation frequency was fstim = 2 Hz, each set of stim-
ulation setups was repeated 10 times, and the break
between stimulation sessions was 10min.
3. Analytical Methods
The fiber type classification was based on the CNAP
conduction velocity and fiber grouping was done into
distinct velocity bands,28 see Fig. 2.
The recorded CNAP waveforms are preprocessed
to ensure that no in-band interferences are present
and to reduce noise in the waveform (Fig. A.3). After
preprocessing, a threshold is applied to the wave-
form and positive/negative peaks above/below the
threshold are detected. The peaks representing fiber
components with distinct velocities were used to con-
struct a velocity profile of the nerve.















A B C1 C2 C3 C4
Fig. 2. CNAP recorded on the SubDiaGVN showing
the stimulation artifact and the different fiber regions,
elicited at stimulation current 1.6 mA, pulsewidth 0.2 ms,
and stimulation frequency 2Hz. The regions are based on
the conduction velocity calculations with the stimulation
and recording sites separated by 8 cm.
3.1. Compound nerve action potentials
A CNAP waveform is the resultant sum of all indi-
vidual fiber action potentials present in the nerve.29
By ensuring that there is enough separation between
stimulation and recording electrodes, as mentioned
in Sec. 2, we were able to obtain better resolution
of CNAP components based on their latencies. An
example of our recordings is shown in Fig. 3.
3.2. Preprocessing
Preprocessing involved comparison of vagal record-
ing channel with the cervical and subdiaphragmatic






























































































































Fig. 3. The CNAPs elicited for three different pulsewidths and 16 different stimulation currents (τpw = 0.1 ms, 0.2 ms,
Istim = 1–3mA and τpw = 0.5 ms, Istim = 1–2mA, see Stimulation Protocol for details): (left) recorded traces, offset by
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CNAPs and interferences, see (Fig. A.3). The elicited
CNAP waveform is aligned with the reference chan-
nels using the stimulation artifact (see Fig. A.2).
Correlation is then used to determine any similar
components present, which will be ignored during
further analysis.
The CNAP waveforms due to 10 repeated stim-
uli are averaged to reduce the noise in recordings
and also to reduce the impact of in-band artifacts,
if present. After averaging, the peaks are detected
above the noise level of the recording system at a
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Fig. 4. (a) CNAP waveforms in which negative/
positive peaks are detected below/above a certain ampli-
tude threshold and the area under the curve is deter-
mined. (b) The peak locations are used to construct a
raster plot showing different fiber events. (c) Fiber events
are used to construct a velocity profile for the fiber.
3.3. Velocity profile
The presence of a peak indicates the activation of a
nerve fiber or a population of nerve fibers with spe-
cific velocity. The distance between the stimulation-
recording electrode and temporal location of the
peaks are used to calculate the velocity of the
CNAP component. The occurrence of a certain fiber
component, known as a fiber event, was noted in the
form of a raster plot, Fig. 4(b). After combining the
number of times the events for a particular fiber type
have occurred, a velocity profile of the nerve is con-
structed, such that the velocity profile represents the
probability density function of different fiber types
represented by different velocities, Fig. 4(c). The
fiber event probability density (FEvPD) is calculated













where n is the total sum of unique fiber events across
all 16 stimulation currents (for a given pulsewidth),
σ is the bandwidth parameter and vi is a fiber event.
K(v) is the kernel function, in our case it is Gaus-
sian. The bandwidth parameter σ corresponds to the
width of the kernel (σ = 0.05 was chosen for all
experiments). It determines the smoothness of the
PDF curve.
The velocity profile of a fiber gives an indication
of the likelihood of excitation and spread in velocity
for a range of currents at a specific pulsewidth. Fur-
ther velocity analysis included determining the fiber
velocity with the highest FEvPD and whether this
changed across pulsewidths and conditions within
the experiment, across animals.
3.4. Strength duration curves
The nerve excitability was studied using strength
duration curves. The stimulation threshold for a
given fiber type or component was defined as the cur-
rent at which the CNAP amplitude for a given fiber
type is above 5 µV. The strength duration curves
were constructed using the Lapicque formula:
Ith =
Irh
1 − eτpw/τm , (2)
where Ith is the threshold current, Irh is the rheobase
current, τpw is the stimulation pulsewidth and τm is
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3.5. Statistical analysis
All numerical data were analyzed by either using
paired t-test or Student’s t-test.
4. Results
Typical results of our CNAP measurements are
shown in Fig. 3, presented for three pulsewidths:
0.1, 0.2 and 0.5ms (measurements for 1ms and 5ms
not shown) and 16 stimulation current levels. The
CNAPs are divided into different velocity regions as
demonstrated in Fig. 2, in order to analyze contribu-
tion from different fiber types.
4.1. Fiber classification
The analysis of CNAP waveform and its velocity pro-
file indicates the presence of different fiber types,
their respective fiber velocities and the effect on the
conduction velocities due to injections.
In Fig. 4(a), example results are shown for iden-
tifying the CNAP peaks and then subsequent gener-
ation of a raster plot based on these peaks, Fig. 4(b).
These plots give a clear indication of the fiber types.
The position of the boundaries between different
fiber types (blue dashed lines) is established on the
basis of fiber velocity calculations. Finally, Fig. 4(c)
presents an FEvPD graph generated from the raster
plot.
4.1.1. Fiber velocity
After the identification of various fiber types, the
range of velocities for each individual fiber type
and the mean velocities are reported in Table 1.
The mean velocities of these different fiber types,
shown in Fig. A.4(a), were significantly different
Table 1. Classification of SubDiaGVN based on velocity
and percentage of fiber events.
Velocity Mean
range velocity Percentage
Fiber type (ms−1) (ms−1) events
Aδ > 4.5 5.1 1.8
B 4.5–2.0 2.47 38.7
C1 2.0–1.2 1.35 31.7
C2 1.2–0.77 0.97 21.6
C3 0.77–0.57 0.62 5.3
C4 < 0.57 0.45 0.81
from each other. We also investigated whether the
fiber velocities were affected by different stimulation
pulsewidths for different fiber types, and found no
difference between them as shown in Fig. A.4(a).
We note that for C1 fibers, a small decrease can be
observed, but with no statistical significance (p =
0.08).
Also, with increase in stimulation current, the C1
fiber velocity distribution will shift towards lower
velocity due to recruitment of slower fibers. This
can be observed on the color map, particularly, for
pulsewidths 0.2ms and 0.5ms, in Fig. 3.
The mean fiber velocities also did not shift sig-
nificantly under different physiological conditions,
Fig. A.4(b). Since fiber velocity does not change
significantly under different stimulation and phys-
iological conditions, it can be used as a parame-
ter to determine fiber damage due to implantation
in an implanted solution or at the end of in vivo
experiments.
4.1.2. Stimulation thresholds
The mean stimulation threshold was determined for
different animals and SD curves were calculated.
The rheobase current for A, B and C1 fibers are
0.28 (± 0.13), 0.46 (± 0.26)mA and 0.66 (± 0.21)mA,
respectively, obtained by fitting the results to
Eq. (2). As observed in the previous papers, the
stimulation thresholds for A fibers are the lowest fol-
lowed by B and C fibers.30
4.2. Effect of CCK
Next, we investigate how various physiological con-
ditions affect the fiber velocity, stimulation threshold
and CNAP amplitude and power. The four different
conditions are described in the methods. The fiber
velocities were not observed to be affected due to
different injections as shown in Fig. A.4. No statisti-
cal differences exist between mean fiber velocity pre-
and post-injections.
4.2.1. Stimulation thresholds and CNAP
amplitude
Figure 5 shows an example of the CNAP wave-
forms on the SubDiaGVN for four different phys-
iological conditions and same stimulation currents
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Fig. 5. An example of variations in stimulation thresh-
olds and CNAP amplitudes under different conditions
(Control, Saline, CCK1, CCK2), for 0.1 ms pulsewidth
and 2 Hz stimulation frequency.
injection of saline has created a change in the CNAP
response: the stimulation threshold increased and the
amplitude was reduced for the stimulation threshold
current. However, additional variations in respect to
the Saline condition are observed for CCK injections.
Systematic investigations of the CCK effects
across different fiber types and animals are shown
in Fig. 6. The left column panels show the results
within first 2min after injections (i.e. when CCK is
active) and the right-hand column panels show the
results starting at 4min after injection, when CCK is
largely absent because its life-time is approximately
2–3min.19,25,31 We find that for myelinated nerve
fibers such as A and B, CNAP components, as shown
in Fig. 6(a), exhibited increased stimulation thresh-
olds. A pairwise t-test indicates statistically signif-
icant differences between stimulation thresholds for
Saline–CCK1 (p = 0.02) and Saline–CCK2 (p =
0.007).
On the contrary, the results for unmyelinated C-
fibers shown in Fig. 7 demonstrate a trend of slightly
lower stimulation thresholds when CCK is active,
however, the result was not statistically significant
enough (p = 0.3).
Additionally, we have investigated the number of
CNAP peaks for all conditions across different ani-
mals, results are shown in Fig. A.5. The figure shows
fiber events normalized to the total fiber events in the
CNAP waveform. The normalized fiber event count




Fig. 6. Effect of injections on CNAPs from myelinated
(a and b) fibers is shown here. A and B fibers exhibit:
(a) higher stimulation threshold currents and (b) CNAP
amplitudes normalized to CNAP amplitudes observed
during Control. Left panels show results up to 90 s after
injections (in the case of CCK injections, CCK will be
still active) and right panels are measurements of 250 s
after injections (when CCK becomes inactive). CCK has
a relatively short half-life in the circulation, approxi-
mately 120–150 s.32 (c) The effect is verified using a pair-
wise t-test on normalized (to Control) stimulation thresh-
old with pSaline−CCK1 = 0.02 and pSaline−CCK2 = 0.007.
for A and B (p = 0.05 for both, using the simple
t-test). Furthermore, the B fibers show significant
decrease when CCK is present compared to Saline
as well (p = 0.03).
5. Discussion
This paper presents the results of a study into the
electrophysiological response of SubDiaGVN, which
is relevant for appetite control. This study is rele-
vant for neurometabolic therapies, which are very
promising neurotechnologies for a number of medi-
cal conditions including obesity and obesity-related
risk factors, such as high cholesterol or high blood
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Fig. 7. Effects of the injections on CNAPs from
unmyelinated (c) fibers, explanations for different pan-
els as in Fig. 6.
elicited in the SubDiaGVN, we were able to identify
the fiber types present in that branch of the vagus
and establish the effect of physiological stimuli, such
as CCK, on the CNAPs.
The methodology described in this paper has
enabled the identification of different fiber types
present in the SubDiaGVN. The nerve stimulation-
recording approach has been previously investigated,
for example, by Tahry et al.33 in human studies of
VNS for epilepsy in order to evaluate the elicited
activation of the nerve, and very recently by Ward
et al.18 to monitor the level of nerve activation. How-
ever, in both cases, the stimulation and recording
sites were close to each other, thus requiring a spe-
cial technique to cancel the stimulation artifact in
order to prevent saturation of the neural recording
amplifier and to resolve CNAP components from the
artifact. It was difficult to clearly identify boundaries
between CNAP components from different fiber
types. In our case, the distance is 8 cm in the rat
model. This enables an easy fiber distinction on the
basis of CNAP conduction velocities. Here, the fiber
classification was done in accordance with the Letter
System,28 with previously established boundaries for
rat vagus.34
A benefit of using CerVN as a preferred stimu-
lation site is that it is a popular stimulation site for
a range of VNS applications, such as epilepsy and
depression. It enables interrogation of the state of
the nerve at any branch of the vagus nerve below
the neck with the same methodology and by chang-
ing only the recording location. Reported side effects
of VNS at CerVN include hoarseness and paresthe-
sia, which, however, exhibit lower long-term inci-
dence.35,36 Clinical studies are used to demonstrate
VNS efficacy for obesity report mild or moderate side
effects such as heartburn, dyspepsia, pain, dysphagia
and nausea.6 Due to recent advances in semiconduc-
tor technology and body area networks, it is possi-
ble to incorporate this methodology in a small size
implant, however, two different incisions are required
and the interrogative stimulation protocol has to
be optimized in order to prevent activation of off-
target pathways, especially, the heart. The stimula-
tion parameters described in this paper did not lead
to a reduction in heart rate. Also, a reason to sepa-
rate the recording and stimulation sites is to improve
resolution of CNAPs originating from different fiber
types. A distance of 8 cm seems acceptable to achieve
good resolution, hence in larger physiological mod-
els, such as humans, a CerVN stimulation site is not
required if the goal is to characterize a specific branch
such as the SubDiaGVN.
5.1. Fiber classification
The analysis of SubDiaGVN CNAPs demonstrates
the presence of primarily A, B and C1 fibers. Other
types of slow C fibers such as C2–C4 were also
observed in some animals, however, not consistently.
The mean fiber velocities for A, B and C fibers
differed significantly (pA−B = 2.5 · 10−4, pA−C =
8.1 · 10−7 and pB−C = 0.002) for pulsewidth of
0.1ms. After variation of pulsewidth, the mean fiber
velocities do not change significantly. As the mean
fiber velocity does not change significantly across
pulsewidths and across conditions, it indicates that
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Fiber distribution, based on the number of fiber
events in CNAPs and hence FEvPD, appears simi-
lar to observations made by Precthl et al.20 where
it was demonstrated that the SubDiaGVN branch
comprises of a majority of unmyelinated fibers such
as C fibers, which carry sensory information.20
The range of stimulation currents (0.1–3mA)
and pulsewidths (0.1–5ms) considered in this
paper covers the traditional range of current and
pulsewidths in use for VNS therapies.33,35,37 The
stimulation thresholds for different fiber types are
significantly different from each other. The rheobase
currents for A, B and C fibers observed in these
experiments are 0.28 (± 0.13), 0.46 (± 0.26) and
0.68 (± 0.21)mA. The thresholds for A and B fibers
are higher than thresholds reported for CerVN in
rats earlier which were in the order of 0.01, 0.03 and
0.2mA.30 Possible reasons could be lower percent-
age of A and B fibers and a higher concentration of
C fibers in the SubDiaGVN branch,20 where signals
were recorded. Other possible reasons could depend
on site of stimulation and type of electrodes used for
stimulation.
5.2. Effect of CCK
To our best knowledge, this study presents the
first results demonstrating the impact of CCK-8 on
CNAPs originating from different fiber types, with-
out nerve fiber dissection. Thus, our study is a con-
tribution to investigations of the interaction between
two different appetite control pathways gut hormone-
hypothalamus and vagus nerve-brainstem, and to the
fundamental question of interaction between the hor-
monal and neural systems. The effect of CCK on
vagal efferents is observed on the stimulation thresh-
old and amplitude of CNAP components originating
from A and B fibers, which become less excitable.
Recent work on the effect of CCK-8 on ventral
gastric vagus nerve which innervates the stomach
shows that intravenous CCK-8 injection produces an
inhibitory effect on efferent fibers and an opposite
effect on afferent fibers using mass activity and fiber
dissection.19 The inhibitory effect on efferent fibers
leads to a reduced gastric tone and contractile activ-
ity, leading to a feeling of satiation.19
The effect of CCK on normalized stimulation
thresholds of CNAPs, observed in this study, can be
detected, hence providing a potential biomarker to
answer when to stimulate. However, no statistically
significant difference was observed between two doses
of CCK used in this study, as shown in Fig. 6, to
allow stimulation dose determination as well. The
dose regulation can be achieved by nerve charac-
terization described here and selecting stimulation
parameters based on this, making the stimulation
dosage patient-specific. As therapeutic peripheral
nerve stimulation requires excitation or blockage of
all or specific fiber type activity, stimulation param-
eters can be intelligently chosen or changed based on
this.
We observed certain differences in CNAP wave-
forms when injecting Saline only. This could be
due to increased blood pressure caused by injec-
tion of additional fluid volume into the vascular sys-
tem and consequent reaction by the vagus nerve
to that change. However, the changes observed due
to CCK are in addition to Saline and statistically
significant.
Furthermore, we observed occasional variations
of the recorded artifact (created by the electrical
stimulation) for various injections. However, they
occur because of input stage filtering (the band pass
filter acts effectively as a differentiator) and insuffi-
cient sampling rate (20 kHz) to observe fast volt-
age transitions. The conclusion is that the stimu-
lus artifact does not show any systematic trends
(e.g. attenuation), and it does not reflect change in
stimulation thresholds for different conditions, see
Fig. B.1.
With current advances in semiconductor technol-
ogy, it is possible to integrate processing algorithms
into implantable devices.2 The AspireSR (Cyberon-
ics) system is a commercially available closed loop
VNS implant to treat epilepsy, in which the ques-
tion when to stimulate is answered by processing
cardiac signals to detect seizure-related ictal tachy-
cardia.11 Recently, we also demonstrated how extra-
cellular pH changes due to the SubDiaGVN activity
can be utilized in the closed loop paradigm.38 Fur-
thermore, we are currently investigating how other
chemical signals of neural activity, such as potassium
ions concentration, could be used for this purpose.
The advantage of using chemical signals would be
better signal to noise ratio in comparison to detect-
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In this study, order effects were not considered.
This is due to our observation that the nerve integrity
has been preserved and the excitability levels have
not shown statistically significant changes as con-
firmed in our stimulation protocol safety study (see
Fig. B.2). Furthermore, there was no overall change
in vitals such as heart rate, throughout the experi-
ment. However, for future studies, randomized order
of physiological conditions can be considered.
6. Conclusion
Neurometabolic therapies are an interesting and
recently discovered area of application for neuro-
modulation devices. However, in such therapies, it
is crucial to understand the impact of physiological
metabolic control systems on neural stimulation and
vice versa, to deliver therapeutic stimulation dosage
in an efficient manner. In this study, an effort has
been made to understand the composition of the
SubDiaGVN and the impact of appetite reducing
gut hormone CCK on its signaling. The motivation
was to use the results for future development of a
closed loop VNS implant which can help link the two
independent appetite control pathways, and through
stimulation amplify the appetite reducing effect of
gut hormone CCK. Existing closed loop systems for
obesity, such as the DiamondTM(Metacure), initiate
stimulation on conduit of food in the stomach. It
is however unclear how the stimulation dose is con-
trolled. In comparison, the methodology proposed
in the paper could enable when and how much to
stimulate and possibly provide greater therapeutic
efficiency by seeking to link metabolic and neural
control pathways. Here, we have shown that CCK
reduces activity of A and B fibers. The inhibitory
effect of the gut hormone, when detected, can be used
as a trigger to initiate stimulation. Furthermore, the
nerve classification protocol and CNAPs can be used
as a means to identify the impact of stimulation on
the state of the nerve, such as percentage activation
or inhibition of specific nerve fiber types.
Further studies will lead us to better understand-
ing of the physiology of the gastric branch of the
vagus nerve and its activity due to other physio-
logical conditions. Ultimately, we might be able to
understand the coding of the nerve in the process of
appetite regulation to design better neurometabolic
therapies for obesity management, appetite control
and weight loss.
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Appendix A
Fig. A.1. (Color online) Left ventral subDiaGVN in a
rat (red circle), from which CNAPs were recorded during
the experiment.
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Fig. A.2. The vagus recording channel is overlaid with
the subdiaphragmatic reference channel, which is used
for comparison to differentiate CNAPs from interferences
(due to movement, EMG, etc.). The inlet shows stimu-
lation artifact alignment for the two channels. In this
example, the CNAPs were elicited at the following stimu-
lation parameters: stimulation current 2mA, pulse width
0.2 ms, and stimulus frequency 2Hz.
Fig. A.3. (Color online) The CNAPs elicited, dur-
ing an experiment, for 16 different currents at 1ms
pulsewidth and 2Hz frequency are shown here. The com-
ponents (encircled in blue) are artifacts common to both
vagus and subdiaphragmatic reference channel. These
peaks/components are ignored during analysis.
(a) (b)
Fig. A.4. Mean fiber velocities and standard deviation for each fiber type and (a) two pulsewidths and (b) different
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Fig. A.5. Variation in the number of peaks for different animals under different conditions: Control, Saline, CCK-low,
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Appendix B
(a)
Fig. B.1. Stimulus artifact under different conditions (Control, Saline, CCK1, CCK2) for 0.1ms pulsewidth and 16
stimulation currents: (a) Experiment shown in Fig. 7, (b) Another experiment. Artifact variability is due to low sampling



































































































April 6, 2018 12:56 1850006





































































































April 6, 2018 12:56 1850006
K. B. Mirza et al.
Fig. B.2. The stimulation protocol was tested for safety
in n = 8 animals. The complete stimulation protocol, five
pulsewidths shown in five panels above, and 16 different
currents (2 Hz stimulation frequency, 10× repeated each
pulsewidth/stimulation current combination and aver-
aged), was repeated three times (Test 1, Test 2, Test 3,
resting time between Tests 10 min) in a similar manner as
described in the paper, however, without any injections.
The stimulation thresholds for A or B fibers in Test 2 and
Test 3 were normalized to the stimulation thresholds of
Test 1, and the mean and standard error are shown. The
normalized stimulation thresholds were not significantly
different from each other. A similar result was obtained
for C fibers. Hence, we conclude that the stimulation pro-
tocols used in our experiments do not affect the nerve
excitability.
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